ALEC - Alector Inc logo

ALEC

Alector Inc

Alector, Inc. develops therapies targeting neurodegenerative diseases, focusing on human monoclonal antibodies and enzyme replacement therapies. Its pipeline includes treatments for Alzheimer's and Parkinson's disease, supported by strategic collaborations with major pharma companies.

โš•๏ธ Healthcare NASDAQ Listed 2019 $ USD
$1,000 invested 5 years ago โ†’$77today

Score Overview

1 Year
Score
Net Growth17.54%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-34.13%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.9
Net Growth-320.70%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth-93.31%
Rev Trend20%
Revenue Consistencyโ€”
All Time
Score
Net Growth-18.08%
Net Trend57%
Net Income Consistency
Rev Growth-34.67%
Rev Trend29%
Revenue Consistency

See the full market ranking โ†’

Alector Inc fundamental performance

Between 2020 and 2025, revenue declined from $ 21M to $ 21M and net income went from -$ 182M to -$ 142M. Revenue increased in 1 of those 5 years; net income in 3.

Alector Inc currently holds a 5-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 2.15โ€”
1 Year2025-08-12
$ 2.007.50%
5 Years2021-08-12
$ 27.91-92.30%
All Time2019-02-07
$ 18.08-88.11%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 13M-$ 117M$ 172M
2025$ 21M-$ 142M$ 256M
2024$ 100M-$ 119M$ 413M
2023$ 97M-$ 130M$ 548M
2022$ 133M-$ 133M$ 712M
2021$ 207M-$ 28M$ 735M
2020$ 21M-$ 182M$ 413M
IPO2019$ 21M-$ 99M$ 353M

Explore beyond ALEC

You're looking at Alector Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies